Topics

Insulet Reports First Quarter 2019 Revenue of $159.6 Million, an Increase of 29% Year-Over-Year

16:01 EDT 2 May 2019 | Businesswire
This article has expired, however you can still download the PDF.
Preview:
Commenced Pod Production at U.S. Manufacturing Facility and Initiated Full U.S. Commercial Launch of Omnipod DASH™ Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin p...

Other Sources for this Article

Investor Relations and Media Contact:
Deborah R. Gordon
Vice President, Investor Relations and Corporate Communications
(978) 600-7717 dgordon@insulet.com

NEXT ARTICLE

More From BioPortfolio on "Insulet Reports First Quarter 2019 Revenue of $159.6 Million, an Increase of 29% Year-Over-Year"

Quick Search

Relevant Topics

Endocrine Disorders
Endocrine disorders are grouped into two categories: hormone imbalance - when a gland produces too much or too little of an endocrine hormone development of lesions (such as nodules or tumors) in the endocrine system, which may or may not affect...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...